Abstract
A significant number of CML patients relapse after discontinuation of therapy, even after achieving DMR, which calls for a need of early biomarkers to discontinue therapy. miRs have a vital role in pathways that decide the pharmacokinetics and pharmacodynamics displayed by a particular patient. Therefore, in this study, we studied the role of miRs to achieve DMR by CML patients on imatinib therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
